GSK plc
GLAXF · OTC
10/28/2025 | 9/30/2025 | 6/30/2025 | 3/31/2025 | |
|---|---|---|---|---|
| Revenue | $8,547,000 | – | $7,986,000 | $7,516,000 |
| % Growth | – | – | 6.3% | – |
| Cost of Goods Sold | $2,258,000 | – | $2,165,000 | $1,937,000 |
| Gross Profit | $6,289,000 | – | $5,821,000 | $5,579,000 |
| % Margin | 73.6% | – | 72.9% | 74.2% |
| R&D Expenses | $1,689,000 | – | $2,024,000 | $1,462,000 |
| G&A Expenses | $2,239,000 | – | $2,140,000 | $2,070,000 |
| SG&A Expenses | $2,239,000 | – | $2,140,000 | $2,070,000 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | -$232,000 | – | -$366,000 | -$169,000 |
| Operating Expenses | $3,696,000 | – | $3,798,000 | $3,363,000 |
| Operating Income | $2,593,000 | – | $2,023,000 | $2,216,000 |
| % Margin | 30.3% | – | 25.3% | 29.5% |
| Other Income/Exp. Net | -$137,000 | – | -$136,000 | -$108,000 |
| Pre-Tax Income | $2,456,000 | – | $1,887,000 | $2,108,000 |
| Tax Expense | $312,000 | – | $241,000 | $336,000 |
| Net Income | $2,013,000 | – | $1,443,000 | $1,624,000 |
| % Margin | 23.6% | – | 18.1% | 21.6% |
| EPS | 2.86 | – | 0.36 | 0.4 |
| % Growth | – | – | -10% | – |
| EPS Diluted | 2.82 | – | 0.35 | 0.39 |
| Weighted Avg Shares Out | 4,034,000 | – | 4,063,000 | 4,088,000 |
| Weighted Avg Shares Out Dil | 4,102,000 | – | 4,110,000 | 4,137,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26,000 | – | $50,000 | $54,000 |
| Interest Expense | $167,000 | – | $184,000 | $162,000 |
| Depreciation & Amortization | $738,000 | – | $1,159,000 | $823,000 |
| EBITDA | $3,361,000 | – | $3,230,000 | $3,093,000 |
| % Margin | 39.3% | – | 40.4% | 41.2% |